MoneyAM MoneyAM
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Indices   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Stock Screener   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in

 
Filter Criteria  
Epic: Keywords: 
From: Time:  (hh:mm) RNS:  MonAM: 
To: Time:  (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above
 


TOP NEWS: ConvaTec increases full-year guidance; interim profit surges

ALN

ConvaTec Group PLC on Wednesday increased its full-year guidance on the back of a boost in profit and a revenue rise in the first half.

The Reading, England-based medical products and technology company said pretax profit in the six months ended June 30 surged by 65% to $76.0 million, from $46.1 million the year prior.

Revenue was up 1.1% to $1.06 billion, from $1.04 billion. This was boosted by the 10% rise in Advanced Wound Care revenue to $338 million, from $307 million in the previous year.

Chief Executive Officer Karim Bitar said: ‘This performance demonstrates the momentum ConvaTec is building, revenue growth is accelerating and we are expanding our operating margin, despite ongoing investments to drive future growth and the challenging inflationary back drop. Given the strength of performance and the encouraging outlook, particularly in Advanced Wound Care, we are increasing our guidance for the full year.’

Selling & distribution expenses increased 6.1% to $304.7 million from $287.3 million year-on-year, which ConvaTec said was driven by higher headcount, and adjusted research & development costs of $4.4 million.

ConvaTec declared an interim dividend of 1.769 US cents, up 3.0% from 1.717 cents the year before, which reflects ‘continued confidence in the future performance’ of the company.

The company increased its full-year guidance, stating it now expected organic revenue growth of between 6.0% to 7.5%, based on the ‘broad-based growth’ across all categories, especially in Advanced Wound Care.

ConvaTec expects its 2023 operating margin to expand to at least 20.5% on a constant currency basis, and adjusted net finance expense for its full year to be towards the upper end of $70 to $80 million previously provided.

‘We have now pivoted to sustainable revenue growth and are focussed on driving margin expansion. We are increasingly confident of delivering sustainable future growth and an operating margin in the mid-20s,’ said ConvaTec.

Shares in ConvaTec were up 4.1% at 214.20 pence in London on Wednesday morning.

Copyright 2023 Alliance News Ltd. All Rights Reserved